

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)
217-9197 (toll free).

Reviewer: Anne Corrigan

Timestamp: Wed Jun 27 16:41:08 EDT 2007

=====

Application No: 10551004

Version No: 1.0

Input Set:**Output Set:****Started:** 2007-06-27 12:08:32.799**Finished:** 2007-06-27 12:08:35.197**Elapsed:** 0 hr(s) 0 min(s) 2 sec(s) 398 ms**Total Warnings:** 63**Total Errors:** 0**No. of SeqIDs Defined:** 82**Actual SeqID Count:** 82

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (1)
W 213	Artificial or Unknown found in <213> in SEQ ID (2)
W 213	Artificial or Unknown found in <213> in SEQ ID (3)
W 213	Artificial or Unknown found in <213> in SEQ ID (4)
W 213	Artificial or Unknown found in <213> in SEQ ID (5)
W 213	Artificial or Unknown found in <213> in SEQ ID (6)
W 213	Artificial or Unknown found in <213> in SEQ ID (7)
W 213	Artificial or Unknown found in <213> in SEQ ID (8)
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (15)
W 213	Artificial or Unknown found in <213> in SEQ ID (18)
W 213	Artificial or Unknown found in <213> in SEQ ID (21)
W 213	Artificial or Unknown found in <213> in SEQ ID (22)
W 213	Artificial or Unknown found in <213> in SEQ ID (23)
W 213	Artificial or Unknown found in <213> in SEQ ID (24)
W 213	Artificial or Unknown found in <213> in SEQ ID (27)
W 213	Artificial or Unknown found in <213> in SEQ ID (28)

Input Set:

Output Set:

Started: 2007-06-27 12:08:32.799
Finished: 2007-06-27 12:08:35.197
Elapsed: 0 hr(s) 0 min(s) 2 sec(s) 398 ms
Total Warnings: 63
Total Errors: 0
No. of SeqIDs Defined: 82
Actual SeqID Count: 82

Error code

Error Description

This error has occurred more than 20 times, will not be displayed

SEQUENCE LISTING

<110> APOGENIX Biotechnology AG

<120> Improved FC Fusion Proteins

<130> 31098PWO-HC

<140> 10551004

<141> 2007-06-27

<150> PCT/EP2004/003239

<151> 2004-03-26

<150> PCT/2004/003239

<151> 2004-03-26

<160> 82

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer
for the amplification of CD95 cDNA

<220>

<223> Sense huCD95-Hind III

<400> 1

tataaagctt gccaccatgc tgggcatctg

30

<210> 2

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primer for
the amplification of CD95 cDNA

<220>

<223> Antisense huCD95-BgI II

<400> 2

tataagatct ggatccttcc tctttgc

27

<210> 3

<211> 30

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
for the amplification of IgG1 Fc cDNA

<220>
<223> Sense hulgG1Fc-BgIII

<400> 3
tataagatct tgtgacaaaa ctcacacatg 30

<210> 4
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer for
the amplification of IgG1 Fc cDNA

<220>
<223> Antisense hulgG1Fc-XhoI

<400> 4
tataactcgag tcattttaccc ggagacaggg 30

<210> 5
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer for
the changing the Kozak Sequence from GCCACCATGC to
GCCGCCACCATGG

<220>
<223> ShuCD95EC_altKozak

<400> 5
tataaagctt gccgccacca tgggtgggcat c 31

<210> 6
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR primer
for the changing the Kozak Sequence from
GCCACCATGC to GCCGCCACCATGG

<220>
<223> AS698 hulgG1Fc-XhoI

<400> 6
tatactcgag tcatttaccc ggagacaggg 30

<210> 7
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
amplifying cDNA of human IgG1 Fc (partial hinge
CH3)

<220>
<223> Sense_hulgG1

<400> 7
ccagggactc ctgcctcttg tgacaaaact cacacatg 38

<210> 8
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer for
amplifying cDNA of human IgG1 Fc (partial hinge
CH3)

<220>
<223> Antisense_ERIhulgG1

<400> 8
tatagaattc tcatttaccc ggagacaggg 30

<210> 9
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer used to
amplify the cDNA of TRAILR2 domain

<220>
<223> Sense_HIII_TRAILR2

<400> 9
tataaagctt gccgccacca tggacaacg gggacagAAC 40

<210> 10
<211> 33

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer used to
 amplify the cDNA of TRAILR2 domain

 <220>
 <223> Antisense_TRAILR2

 <400> 10
 gtgagttttg tcacaagagg caggagtccc tgg 33

 <210> 11
 <211> 40
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer for PCR
 used to utilize fragments for cloning purposes

 <220>
 <223> Sense_HIII_TRAILR2

 <400> 11
 tataaagctt gccgccacca tggaacaacg gggacagaac 40

 <210> 12
 <211> 30
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: primer for
 PCR used to utilize fragments for cloning
 purposes

 <220>
 <223> Antisense_ERIhulgG1

 <400> 12
 tatagaattc tcatttaccc ggagacaggg 30

 <210> 13
 <211> 335
 <212> PRT
 <213> human

 <220>
 <223> CD95 >sp/P25445/TNR6_HUMAN Tumor necrosis factor
 receptor superfamily 6 precursor (FASL-receptor)
 (Apoptosis-mediating surface antigen FAS) (Apo-1
 antigen) (CD95) - Homo sapiens (Human)

<400> 13

Met	Leu	Gly	Ile	Trp	Thr	Leu	Leu	Pro	Leu	Val	Leu	Thr	Ser	Val	Ala	
1				5					10					15		
Arg	Leu	Ser	Ser	Lys	Ser	Val	Asn	Ala	Gln	Val	Thr	Asp	Ile	Asn	Ser	
			20					25					30			
Lys	Gly	Leu	Glu	Leu	Arg	Lys	Thr	Val	Thr	Thr	Val	Glu	Thr	Gln	Asn	
	35						40					45				
Leu	Glu	Gly	Leu	His	His	Asp	Gly	Gln	Phe	Cys	His	Lys	Pro	Cys	Pro	
	50					55					60					
Pro	Gly	Glu	Arg	Lys	Ala	Arg	Asp	Cys	Thr	Val	Asn	Gly	Asp	Glu	Pro	
65					70					75					80	
Asp	Cys	Val	Pro	Cys	Gln	Glu	Gly	Lys	Glu	Tyr	Thr	Asp	Lys	Ala	His	
				85					90						95	
Phe	Ser	Ser	Lys	Cys	Arg	Arg	Cys	Arg	Leu	Cys	Asp	Glu	Gly	His	Gly	
			100					105						110		
Leu	Glu	Val	Glu	Ile	Asn	Cys	Thr	Arg	Thr	Gln	Asn	Thr	Lys	Cys	Arg	
	115						120					125				
Cys	Lys	Pro	Asn	Phe	Phe	Cys	Asn	Ser	Thr	Val	Cys	Glu	His	Cys	Asp	
	130					135					140					
Pro	Cys	Thr	Lys	Cys	Glu	His	Gly	Ile	Ile	Lys	Glu	Cys	Thr	Leu	Thr	
145					150					155					160	
Ser	Asn	Thr	Lys	Cys	Lys	Glu	Glu	Gly	Ser	Arg	Ser	Asn	Leu	Gly	Trp	
			165						170					175		
Leu	Cys	Leu	Leu	Leu	Leu	Pro	Ile	Pro	Leu	Ile	Val	Trp	Val	Lys	Arg	
		180						185						190		
Lys	Glu	Val	Gln	Lys	Thr	Cys	Arg	Lys	His	Arg	Lys	Glu	Asn	Gln	Gly	
	195						200					205				
Ser	His	Glu	Ser	Pro	Thr	Leu	Asn	Pro	Glu	Thr	Val	Ala	Ile	Asn	Leu	
	210					215					220					
Ser	Asp	Val	Asp	Leu	Ser	Lys	Tyr	Ile	Thr	Thr	Ile	Ala	Gly	Val	Met	
225					230					235					240	
Thr	Leu	Ser	Gln	Val	Lys	Gly	Phe	Val	Arg	Lys	Asn	Gly	Val	Asn	Glu	
			245						250					255		
Ala	Lys	Ile	Asp	Glu	Ile	Lys	Asn	Asp	Asn	Val	Gln	Asp	Thr	Ala	Glu	
		260					265						270			
Gln	Lys	Val	Gln	Leu	Leu	Arg	Asn	Trp	His	Gln	Leu	His	Gly	Lys	Lys	
	275						280						285			
Glu	Ala	Tyr	Asp	Thr	Leu	Ile	Lys	Asp	Leu	Lys	Lys	Ala	Asn	Leu	Cys	

290	295	300
Thr Leu Ala Glu Lys Ile Gln Thr Ile Ile Leu Lys Asp Ile Thr Ser		
305	310	315 320
Asp Ser Glu Asn Ser Asn Phe Arg Asn Glu Ile Gln Ser Leu Val		
	325	330 335

<210> 14
 <211> 330
 <212> PRT
 <213> human

<220>
 <223> IgG1 > sp/P01857/GC1_HUMAN Ig gamma-1 chain C
 region - Homo sapiens (Human)

<400> 14

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys		
1	5	10 15
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr		
	20	25 30
Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser		
	35	40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser		
	50	55 60
Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr		
	65	70 75 80
Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys		
	85	90 95
Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys		
	100	105 110
Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro		
	115	120 125
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys		
	130	135 140
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp		
	145	150 155 160
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu		
	165	170 175
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu		
	180	185 190
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn		

195

200

205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu
 225 230 235 240

Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 15

<211> 400

<212> PRT

<213> Artificial Sequence

<220>

<221> MUTAGEN

<222> (1)..(400)

<223> CD95-Fc fusion protein (AA 1-172 CD95 and AA
 102-330 IgG1)

<220>

<223> Description of Artificial Sequence: fusion protein

<400> 15

Met Leu Gly Ile Trp Thr Leu Leu Pro Leu Val Leu Thr Ser Val Ala
 1 5 10 15

Arg Leu Ser Ser Lys Ser Val Asn Ala Gln Val Thr Asp Ile Asn Ser
 20 25 30

Lys Gly Leu Glu Leu Arg Lys Thr Val Thr Thr Val Glu Thr Gln Asn
 35 40 45

Leu Glu Gly Leu His His Asp Gly Gln Phe Cys His Lys Pro Cys Pro
 50 55 60

Pro Gly Glu Arg Lys Ala Arg Asp Cys Thr Val Asn Gly Asp Glu Pro
 65 70 75 80

Asp	Cys	Val	Pro	Cys	Gln	Glu	Gly	Lys	Glu	Tyr	Thr	Asp	Lys	Ala	His		
				85					90					95			
Phe	Ser	Ser	Lys	Cys	Arg	Arg	Cys	Arg	Leu	Cys	Asp	Glu	Gly	His	Gly		
			100					105					110				
Leu	Glu	Val	Glu	Ile	Asn	Cys	Thr	Arg	Thr	Gln	Asn	Thr	Lys	Cys	Arg		
		115						120					125				
Cys	Lys	Pro	Asn	Phe	Phe	Cys	Asn	Ser	Thr	Val	Cys	Glu	His	Cys	Asp		
		130					135					140					
Pro	Cys	Thr	Lys	Cys	Glu	His	Gly	Ile	Ile	Lys	Glu	Cys	Thr	Leu	Thr		
145					150					155					160		
Ser	Asn	Thr	Lys	Cys	Lys	Glu	Glu	Gly	Ser	Arg	Ser	Cys	Asp	Lys	Thr		
				165					170					175			
His	Thr	Cys	Pro	Pro	Cys	Pro	Ala	Pro	Glu	Leu	Leu	Gly	Gly	Pro	Ser		
			180					185					190				
Val	Phe	Leu	Phe	Pro	Pro	Lys	Pro	Lys	Asp	Thr	Leu	Met	Ile	Ser	Arg		
		195						200				205					
Thr	Pro	Glu	Val	Thr	Cys	Val	Val	Val	Asp	Val	Ser	His	Glu	Asp	Pro		
		210				215					220						
Glu	Val	Lys	Phe	Asn	Trp	Tyr	Val	Asp	Gly	Val	Glu	Val	His	Asn	Ala		
225					230					235					240		
Lys	Thr	Lys	Pro	Arg	Glu	Glu	Gln	Tyr	Asn	Ser	Thr	Tyr	Arg	Val	Val		
				245					250					255			
Ser	Val	Leu	Thr	Val	Leu	His	Gln	Asp	Trp	Leu	Asn	Gly	Lys	Glu	Tyr		
			260					265					270				
Lys	Cys	Lys	Val	Ser	Asn	Lys	Ala	Leu	Pro	Ala	Pro	Ile	Glu	Lys	Thr		
		275					280						285				
Ile	Ser	Lys	Ala	Lys	Gly	Gln	Pro	Arg	Glu	Pro	Gln	Val	Tyr	Thr	Leu		
		290				295					300						
Pro	Pro	Ser	Arg	Glu	Glu	Met	Thr	Lys	Asn	Gln	Val	Ser	Leu	Thr	Cys		
305					310				315						320		
Leu	Val	Lys	Gly	Phe	Tyr	Pro	Ser	Asp	Ile	Ala	Val	Glu	Trp	Glu	Ser		
				325					330					335			
Asn	Gly	Gln	Pro	Glu	Asn	Asn	Tyr	Lys	Thr	Thr	Pro	Pro	Val	Leu	Asp		
			340					345					350				
Ser	Asp	Gly	Ser	Phe	Phe	Leu	Tyr	Ser	Lys	Leu	Thr	Val	Asp	Lys	Ser		
		355					360						365				
Arg	Trp	Gln	Gln	Gly	Asn	Val	Phe	Ser	Cys	Ser	Val	Met	His	Glu	Ala		
		370				375						380					

Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
385 390 395 400

<210> 16
<211> 43
<212> PRT
<213> human

<220>
<223> CD95 extracellular domain (AA 131-173)

<400> 16
Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
1 5 10 15

Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn
20 25 30

Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Asn
35 40

<210> 17
<211> 22
<212> PRT
<213> human

<220>
<223> huIgG1 (AA 99-120)

<400> 17
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
1 5 10 15

Pro Glu Leu Leu Gly Gly
20

<210> 18
<211> 60
<212> PRT
<213> Artificial Sequence

<220>
<223> CD95-Fc fusion protein of CD95 extracellular
domain (AA 131-173) and huIgG1 (AA99-120) with an
overlapping amino acid (CD95 AA 172 and huIgG1 AA
102)

<220>

<223> Description of Artificial Sequence: fusion
protein

<400> 18

Pro Asn Phe Phe Cys Asn Ser Thr Val Cys Glu His Cys Asp Pro Cys
1 5 10 15

Thr Lys Cys Glu His Gly Ile Ile Lys Glu Cys Thr Leu Thr Ser Asn
20 25 30

Thr Lys Cys Lys Glu Glu Gly Ser Arg Ser Cys Asp Lys Thr His Thr
35 40 45

Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
50 55 60

<210> 19

<211> 468

<212> PRT

<213> human

<220>

<223> TRAIL-R1 >sp/000220/T10A_HUMAN Tumor necrosis
factor receptor superfamily member 10A precursor
(Death receptor 4) (TNF-related
apoptosis-including ligand receptor 1) (TRAIL
receptor-1) (TRAIL-R1)

<400> 19

Met Ala Pro Pro Pro Ala Arg Val His Leu Gly Ala Phe Leu Ala Val
1 5 10 15

Thr Pro Asn Pro Gly Ser Ala Ala Ser Gly Thr Glu Ala Ala Ala Ala
20 25 30

Thr Pro Ser Lys Val Trp Gly Ser Ser Ala Gly Arg Ile Glu Pro Arg
35 40 45

Gly Gly Gly Arg Gly Ala Leu Pro Thr Ser Met Gly Gln His Gly Pro
50 55 60

Ser Ala Arg Ala Arg Ala Gly Arg Ala Pro Gly Pro Arg Pro Ala Arg
65 70 75 80

Glu Ala Ser Pro Arg Leu Arg Val His Lys Thr Phe Lys Phe Val Val
85 90 95

Val Gly Val Leu Leu Gln Val Val Pro Ser Ser Ala Ala Thr Ile Lys
100 105 110

Leu His Asp Gln Ser Ile Gly Thr Gln Gln Trp Glu His Ser Pro Leu
115 120 125

Gly Glu Leu Cys Pro Pro Gly Ser His Arg Ser Glu His Pro Gly Ala

130			135			140									
Cys	Asn	Arg	Cys	Thr	Glu	Gly	Val	Gly	Tyr	Thr	Asn	Ala	Ser	Asn	Asn
145			150			155			160						
Leu	Phe	Ala	Cys	Leu	Pro	Cys	Thr	Ala	Cys	Lys	Ser	Asp	Glu	Glu	Glu
165			170			175									
Arg	Ser	Pro	Cys	Thr	Thr	Thr	Arg	Asn	Thr	Ala	Cys	Gln	Cys	Lys	Pro
180			185			190									
Gly	Thr	Phe	Arg	Asn	Asp	Asn	Ser	Ala	Glu	Met	Cys	Arg	Lys	Cys	Ser
195			200			205									
Arg	Gly	Cys	Pro	Arg	Gly	Met	Val	Lys	Val	Lys	Asp	Cys	Thr	Pro	Trp
210			215			220									
Ser	Asp	Ile	Glu	Cys	Val	His	Lys	Glu	Ser	Gly	Asn	Gly	His	Asn	Ile
225			230			235			240						
Trp	Val	Ile	Leu	Val	Val	Th									